Loss of type III transforming growth factor-Β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma

Oncogene

Volumn 29, Issue 20, 2010, Pages 2905-2915

  Cooper, S J ^a   Zou, H ^b,e   Legrand, S N ^a   Marlow, L A ^a   Von Roemeling, C A ^a   Radisky, D C ^a   Wu, K J ^a   Hempel, N ^c,f   Margulis, V ^d   Tun, H W ^a   Blobe, G C ^c   Wood, C G ^d   Copland, J A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Exact Sciences Corporation   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Clear cell renal cell carcinoma; GATA3; Methylation; Transcriptional regulation; Type III transforming growth factor receptor

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; METHYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA METHYLATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LUCIFERASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 77952675064     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.64     Document Type: Article

References (35)

1. Chakravarthy D, Green AR, Green VL, Kerin MJ, Speirs V. (1999). Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. Int J Oncol 15: 187-194.
2. Cooper S, Ranger-Moore J, Bowden TG. (2005). Differential inhibition of UVB-induced AP-1 and NF-kappaB transactivation by components of the jun bZIP domain. Mol Carcinog 43: 108-116. (Pubitemid 40781164)
3. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H et al. (2003). Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22: 8053-8062. (Pubitemid 37175870)
4. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA et al. (2006). Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25: 2304-2317.
5. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N et al. (2007). The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117: 206-217. (Pubitemid 46048467)
6. Elliott RL, Blobe GC. (2005). Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093. (Pubitemid 46211385)
7. Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. (2008). bRIII suppresses non-small cell lung cancer inv. Carcinogenesis 29: 528-535.
8. Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R et al. (2005). Inhibin a-subunit and the inhibin coreceptor be. Eur J Endocrinol 152: 277-284.
9. Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. (2008). Loss of type III transforming growth factor b re. Carcinogenesis 29: 252-262.
10. Grote D, Souabni A, Busslinger M, Bouchard M. (2006). Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 133: 53-61. (Pubitemid 43169320)
11. Gulbinas A, Berberat PO, Dambrauskas Z, Giese T, Giese N, Autschbach F et al. (2006). Aberrant gata-3 expression in human pancreatic cancer. J Histochem Cytochem 54: 161-169. (Pubitemid 43201637)
12. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN et al. (2007). Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749. (Pubitemid 47294780)
13. Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA et al. (2008). Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis 29: 905-912. (Pubitemid 351993040)
14. Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. (2007). Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 67: 5231-5238. (Pubitemid 46997261)
15. Ho IC, Pai SY. (2007). GATA-3\not just for Th2 cells anymore. Cell Mol Immunol 4: 15-29.
16. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ et al. (2008a). GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152. (Pubitemid 351163164)
17. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. (2008b). GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20: 164-170.
18. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041-1055. (Pubitemid 44792255)
19. Labastie MC, Catala M, Gregoire JM, Peault B. (1995). The GATA-3 gene is expressed during human kidney embryogenesis. Kidney Int 47: 1597-1603.
20. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Lopez-Casillas F, Riquelme C, Perez-Kato Y, Ponce-Castaneda MV, Osses N, Esparza-Lopez J et al. (2003). Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta. J Biol Chem 278: 382-390. (Pubitemid 36043587)
22. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG. (2008). Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. Clin Cancer Res 14: 5722-5730.
23. Massague J. (2008). TGFbeta in Cancer. Cell 134: 215-230.
24. McCarthy TL, Pham TH, Knoll BI, Centrella M. (2007). Prostaglan-din E2 increases transforming growth factor-beta type III receptor expression through CCAAT enhancer-binding protein delta in osteoblasts. Mol Endocrinol 21: 2713-2724. (Pubitemid 350035153)
25. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D et al. (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65: 11259-11264. (Pubitemid 41821679)
26. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540. (Pubitemid 29368255)
27. Mythreye K, Blobe GC. (2009). The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrest-in2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106: 8221-8226.
28. Sharifi N, Hurt EM, Kawasaki BT, Farrar WL. (2007). TGFBR3 loss and consequences in prostate cancer. The Prostate 67: 301-311. (Pubitemid 46255788)
29. Pantuck AJ, Zisman A, Belldegrun AS. (2001). The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623. (Pubitemid 34225128)
30. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D et al. (2003). Heart and liver defects and reduced transforming gro. Mol Cell Biol 23: 4371-4385.
31. Tavares TS, Nanus D, Yang XJ, Gudas LJ. (2008). Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 7: 1607-1618.
32. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. (2007). The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67: 1090-1098. (Pubitemid 46270765)
33. Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, Vanderlinden G et al. (2000). GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406: 419-422. (Pubitemid 30625562)
34. Wood CG. (2007). Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 13: 697s-702s.
35. You HJ, How T, Blobe GC. (2009). The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis 30: 1281-1287.